Hanmi Science Co., Ltd.

South Korea

  • 1m
  • 3m
  • 6m
  • 1y
  • 2y
  • 5y
Nov 23, 2017
Prev close: 114,500
Nov 23, 2017
Market cap:
Market cap(USD):
Shares: 62.27M

Currency in KRW

Company profile

Market(Ticker): KRX(008930)
Health Technology
Pharmaceuticals: Other
Full time employees: --

Business summary

Hanmi Science Co., Ltd. is a holding company that engages in the management of its subsidiaries. It is mainly engaged in the manufacturing and selling of pharmaceutical ingredients and intermediates. The company was founded on June 15,1973 and is headquartered in Hwaseong, South Korea.

Company background

Hanmi Science is a holding company with two core subsidiaries: Hanmi Pharmaceutical, which develops and produces medicines, and Online Pharm, a drug wholesaler. In recent years, the South Korean group has been actively developing new drugs. It has also accelerated overseas expansion, including by setting up a unit in Beijing.

The company's market capitalization puts it in the top tier of South Korean drug companies, alongside Celltrion.

The group was established in 1973 as Hanmi Pharmaceutical. It strengthened its presence in the drug development game in the 2000s. About 20% of sales are reinvested in research and development.

Hanmi has been focusing on clinical trials for diabetes treatments. It expects the diabetes drug market to grow at an average annual pace of over 6% from 2014 to 2023, nearly doubling in size to $42 billion.

The company's operations include original design manufacturing services for major international drugmakers, including France's Sanofi. For this, Hanmi uses a plant in Hwaseong, Gyeonggi Province. It also runs a facility for antibiotics and biotechnology in Pyeongtaek, in the same province.

Hanmi Fine Chemical, another group company, produces active pharmaceutical ingredients for major drugmakers.

In July 2015, Hanmi announced a partnership with German drugmaker Boehringer Ingelheim. The duo aims to develop a pharmaceutical candidate, HM61713, into a new molecularly targeted drug for lung cancer treatment. Hanmi is to put the drug through clinical trials in South Korea, China and Hong Kong, as well as handle sales licensing, production and commercialization in those markets.

Under the deal, Hanmi will start by using $50 million in contract money to conduct clinical development. The South Korean company stands to receive a total of $730 million, based on progress with licensing and other tasks.

In the news

Financial highlights

Dec 2016

  • Local currency
  • US Dollar
Revenue 665,284.66M
Gross profit 26,141.61M
Operating income 15,067.31M
Income before tax 5,329.86M
Net income 7,937.68M
EBITDA 18,272.20M
Diluted EPS 130.84
Dividends per share 428.15
Total assets 969,248.66M
Total liabilities 321,684.81M
Total equity 645,286.62M
Operating cash flow 85,043.35M

Currency in KRW

Revenue 573.42M
Gross profit 22.53M
Operating income 12.98M
Income before tax 4.59M
Net income 6.84M
Diluted EPS 0.11
Dividends per share 0.36
Total assets 802.49M
Total liabilities 266.33M
Total equity 534.26M
Operating cash flow 73.30M

Currency in USD

Valuation measures

Dec 2016

PER 436.42
ROA 0.83%
ROE 1.29%
Operating margin 2.26%
Profit margin 1.19%

Key executive

  • Co-President, Chief Executive Officer & Director: Jong-Yoon Lim
  • Co-President & Director: Sae-Chang Kwon
  • Director & Vice President: Jae-Sik Kim
  • Co-President & Director: Jong-Soo Woo
  • Executive Board Member: Yu-Shik Hwang

Share holders

  • LIM SUNG-GI(34.2%)
  • SHIN DONG-GUK(12.1%)
  • Hanmi IT(6.4%)
  • LIM JONG-YOON(3.5%)
  • LIM JU-HYUN(3.5%)
  • LIM JONG-HOON(3.1%)
  • Hanmi Science Co., Ltd.(2.2%)
  • LIM JIN-HEE(2.2%)


  • Website:
  • Address: 214 Muha-ro, Paltan-myeon, Hwaseong-si, 18536, South Korea
  • Phone: +82.31.350.5600

Copyright © 2017 FactSet Research Systems Inc. All rights reserved.